Many drugs used in cardiology act by changing the gating properties of ion channels. This is true for Cal+ antagonists which are blockers of voltage-operated L-type Ca2+ channels and for most antiarrhythmics. Class I agents are blockers of Na+ channels whereas class III antiarrhythmics prolong the cardiac action potential by blockade of K+ channels.' In the past decade much has been learnt about the physiology and pharmacology of ion channels. Pharmacological agents that selectively open K+ channels have been developed and this novel group of drugs is rapidly expanding.23 K+ channel openers are peripheral and coronary vasodilators45 but they additionally act on the myocardium and seem to protect it from damage during ischaemia and reperfusion.67
Basic aspects of K+ channels K+ CHANNELS AND MEMBRANE POTENTIAL K+ channels play a key role in the regulation of membrane potential and cell excitability and the function of these channels contributes to the electrical and mechanical properties of the heart and vasculature. The concentration of K+ inside cells (150 mM) is much higher than outside (3-5 mM) due to the action of the Na+/K+ pump. Opening of K+ channels makes K+ ions flow out of the cell along the outward directed electrochemical gradient for K+. This changes the membrane potential in a hyperpolarising direction. It becomes more negative and is moved towards the K+ equilibrium potential. In contrast, blockade of K+ channels shifts the membrane potential in a depolarising direction. In the heart, repolarisation of the cardiac action potential is largely caused by opening of K+ channels.' Membrane depolarisation and hyperpolarisation through blockade and opening of K+ channels are also important mechanisms regulating vascular smooth muscle contraction and relaxation.8 DIVERSITY OF K+ CHANNELS K+ channels are the most heterogeneous of all ion channels. So far at least 16 major types of K+ channels have been characterised and several subtypes exist within each major type of K+ channel. Each type of K+ channel serves a distinct function and the expression of K+ channels differs among tissues and organs. This high degree of diversity opens the fascinating possibility that pharmacologically selective openers or blockers of a specific K+ channel subtype may be developed to modulate specialised tissue functions. Identification of the different types of K+ channels have been made possible largely because of the development of the electrophysiological patch-clamp method which allows ion channels to be investigated at a single channel level. By this method it is possible to determine factors which open and close a channel (the gating properties) as well as the single channel conductance which is a measure of how easily ions flow through a channel (measured in pico Siemens). These variables are used to characterise and classify specific types of K+ channels. K+ channels can be divided into three major classes on basis of their gating properties: those that are gated by ligands such as ATP, Ca2+, neurotransmitters or G-proteins (ligand gated), those gated by changes in membrane potential (voltage gated) and those gated both by ligands and voltage. The voltage-gated K+ channels can be subdivided into outward or delayed rectifiers which are activated by cell membrane depolarisation and inward rectifiers which are closed by depolarisation.
Several K+ channels have now been cloned thus allowing the molecular and structural basis of the diversity of K+ channels to be determined. 9 On the basis of molecular structure two major super-families of K+ channels can be discriminated. The S4 superfamily (fig 1) , to which voltage-gated delayed rectifier K+ channels belong, is built up of large protein subunits of six membrane-spanning a-helical segments (S 1-S6) and a seventh hairpinshaped segment interposed between S5 and S6. The seventh segment forms a major part of the K+ channel pore itself (P-region) while S4 is belived to be the voltage sensor. K+ Regional haemodynamic studies have shown that these drugs preferentially produce coronary vasodilatation.5 The K+ channel opener aprikalim even produces coronary vasodilatation in doses that have no effect on blood pressure.5 In vitro these drugs produce coronary vasorelaxation when the endothelium is present or when it is removed. Cromakalim, pinacidil, and nicorandil dilate large epicardial coronary arteries as well as small coronary resistance arteries in vivo. However, damage of the endothelium by balloon angioplasty in dogs greatly reduced the dilatation of large coronary arteries by cromakalim and pinacidil whereas that produced by nicorandil was unaffected.30
Cromakalim and pinacidil therefore seem to dilate large coronary arteries in vivo partly by an endothelium-dependent mechanism possibly induced by an increase in proximal flow caused by dilatation of the small coronary resistance vessels. The endothelium-independent coronary vasodilatation of large coronary arteries produced by nicorandil is probably mediated by the additional nitrate action of the drug. MYOCARDIUM K+ channel openers only influence the function of the non-ischaemic myocardium at concentrations that are much higher than those required for vascular smooth muscle relaxation. At such high concentrations these drugs shorten cardiac action potential duration and depress cardiac contractility.6 However, at much lower concentrations these drugs exert cardioprotective actions, with some KATP openers acting at concentrations which produce only minimal haemodynamic effects. 3 8 Gross and Auchampach39 first showed that glibenclamide abolished the cardioprotective effect of preconditioning in dogs and that a KATP opener aprikalim mimicked the effect of preconditioning without producing any systemic haemodynamic effects. Later studies in dogs and pigs supported an essential role for KATP in preconditioning, whereas results of studies in rabbits and rats were somewhat conflicting.'8 In a recent study by Yao and Gross,40 transient occlusion of the left anterior descending coronary artery (LAD) for only 3 min had no preconditioning effect. However, when bimakalim was given during the LAD occlusion period a significant preconditioning effect was seen. Bimakalim infusion alone did not influence infarct size, thus suggesting that pharmacological activation of KATP can sensitise the myocardium to preconditioning. Glibenclamide also blocks preconditioning in man.4' In patients with angina pectoris, coronary angioplasty with two subsequent balloon inflations resulted in markedly reduced ST segment changes and pain during the second balloon inflation. The beneficial preconditioning effect of the first inflation was completely abolished by glibenclamide given in an oral dose used in antidiabetic treatment.
Previous studies have also suggested a role for adenosine in mediating ischaemic preconditioning. Adenosine acts through adenosine receptor stimulation in the myocardium and activates KATP by a G-protein regulated mechanism.'5 Thus it seems likely that KATP opening is the mechanism whereby adenosine produces its protective effect. This is supported by the observation that glibenclamide in dogs completely blocked the ability of exogenously administered adenosine to mimic preconditioning.42 ELECTROPHYSIOLOGICAL ASPECTS Concern has been raised that K+ channel openers may possibly be proarrhythmic because of their ability to shorten cardiac action potential duration (APD), an effect that is expected to reduce cardiac refractoriness. However, shortening of cardiac APD may be both proarrhythmic and antiarrhythmic depending on the type of arrhythmia in question and the state of the myocardium. As a consequence there are experimental studies reporting proarrhythmic, not proarrhythmic, and antiarrhythmic effects with these drugs.4345 In the non-ischaemic myocardium, only very high and clinically irrelevant concentrations produce shortening of APD and a tendency to arrhythmias. In contrast, clinically relevant concentrations inhibit arrhythmias induced by triggered activity (early and late afterdepolarisations) which are of relevance in the long QT syndrome and torsades de pointes ventricular tachycardia. In the ischaemic myocardium, which favours reentry arrhythmias, these drugs shorten cardiac APD at clinically relevant concentrations and may facilitate arrhythmias. Whereas several studies have shown no proarrhythmia or even antiar-rhythmic activity of K+ channel openers in animal models of ischaemia-induced arrhythmias others have shown that proarrhythmias may be a risk particularly at the high concentrations that produce profound hypotension. In this context, K+ channel openers by their cardioprotective action may produce indirect antiarrhythmic effects in myocardial ischaemia. To date, pinacidil and nicorandil have been given to thousands of patients without reports of adverse arrhythmias. If the cardioprotective effect can be separated from the ability of these drugs to shorten cardiac APD, and some observations have suggested that they can,37 it should be possible to develop cardioprotective KATP openers without or with only a minimal proarrhythmic potential.
The ST segment and T wave changes in the electrocardiogram during myocardial ischaemia are believed to result from enhanced outwardly directed K+ currents. K+ channel openers may therefore mimic such changes even in the absence of myocardial ischaemia. Changes consisting of inversion or flattening of the T wave have been reported in 30% of patients treated with pinacidil.46 Even though such changes are benign, they may give rise to difficulties in the interpretation of the electrocardiogram, particularly in patients with ischaemic heart disease.
Therapeutic potential of K+ channel openers ANGINA 
PECTORIS
Coronary vasodilatation induced by hypoxia/ ischaemia is an endogenous beneficial mechanism which operates to improve perfusion of the ischaemic myocardium. The role of KA,P in mediating metabolic coronary vasodilatation makes KATP openers of potential interest in the treatment of angina pectoris. In addition, these vasorelaxant drugs preferentially produce coronary vasodilatation, some of them even without systemic haemodynamic changes. Their ability to inhibit myocardial stunning, limit myocardial infarct size, and mimic ischaemic preconditioning may further stimulate the interest in these drugs in coronary artery disease. However, although clinical trials have been initiated, there are currently no clinical data on pure K+ channel openers in patients with ischaemic heart disease.
Clinical data are available for nicorandil47 48 which is now in clinical use as an antianginal agent. Although it is classified as a K+ channel opener it is not a pure one, but a hybrid between a nitrate and a KATP opener. Nicorandil has proved effective for the treatment of stable angina pectoris in placebo controlled clinical trials, and in comparative studies it shows the same degree of antianginal efficacy as nitrates, Ca2+ antagonists, and ,B adrenoceptor blockers. In addition, clinical data indicate that it might be useful in the treatment of unstable angina and variant angina.
Nicorandil dilates large coronary arteries and has balanced preload and afterload reducing effects because of its nitrate and KATP opener components, respectively. It increases cardiac output by haemodynamic changes and may be used in patients with poor left ventricular function. Interestingly nicorandil, unlike the nitrates, does not seem to induce the development of tolerance.
CARDIOPROTECTION
The cardioprotective effect of KATP openers is a most fascinating aspect of these new drugs. It implies that they may be able not only to prevent and relieve the symptoms of myocardial ischaemia but also to reduce some of the important consequences of myocardial ischaemia such as myocardial stunning and infarction. If this holds true in clinical practice, it is likely that these drugs will be of longterm benefit and reduce mortality in patients with ischaemic heart disease. These drugs may also have a therapeutic potential as adjuvant treatment in coronary angioplasty and coronary bypass surgery to protect the myocardium from ischaemic injury and to inhibit postoperative myocardial stunning.
HEART FAILURE Hybrid drugs between nitrates and KATP openers such as nicorandil have a balanced haemodynamic profile of preload and afterload reduction.48 This effect profile resembles that produced by the combined treatment of isosorbide dinitrate and hydralazine which was used in the V-HeFT studies. In the V-HeFT II study the ACE inhibitor enalapril was superior to isosorbide dinitrate and hydralazine in terms of mortality, whereas the latter combination was superior to enalapril in improving left ventricular function and exercise capacity of the patients. Nicorandil has so far shown favourable haemodynamic actions in heart failure in small short-term clinical studies. Vasodilators have been unsuccessful in the treatment of intermittent claudication probably because they dilate vessels supplying normally perfused skeletal muscle and thereby divert blood flow away from the ischaemic tissue. In contrast to other vasodilators K+ channel openers seem to enhance blood flow to ischaemic skeletal muscle and improve recovery of muscle energy stores in animal models of chronic occlusive arterial disease.49 These beneficial effects were manifest at doses below those affecting systemic blood pressure and may reflect redistribution of blood flow to ischaemic muscle due to selective dilatation of collateral vessels. Hypersensitivity of such vessels to K+ channel openers might arise because ischaemic conditions would favour opening of KATP. Another possible explanation could be differences in nerve supply and populations of K+ channels between collaterals and other vessels. Clinical studies on the effect of K+ channel openers in patients with peripheral vascular disease have started.
IMPLICATIONS FOR DIABETIC PATIENTS
TREATED WITH SULPHONYLUREA KA,P BLOCKERS Diabetes mellitus is an adverse risk factor in acute myocardial infarction. These patients have a poor prognosis after infarction with a three to four fold higher mortality risk than non-diabetics. The reason why diabetic patients do so badly is unclear. Non-insulindependent diabetes mellitus (NIDDM) accounts for 85% of all cases of diabetes and most of these patients are treated with oral antidiabetic sulfonylureas which can block not only pancreatic KATP channels but also cardiovascular KATP channels. The question arises whether treatment with antidiabetic sulfonylureas is hazardous from a cardiovascular point of view. In a large multicentre trial with an eight year observation period a twofold increase in cardiovascular mortality was observed among patients treated with tolbutamide when compared with placebo or insulin treated patients,90 but the validity of this conclusion has been questioned and is the subject of much debate.9' If the knowledge derived from basic science of the interaction between antidiabetic sulfonylureas and cardiovascular KATP channels is clinically relevant the use of sulfonylureas in patients with diabetes should be considered carefully. Conclusion K+ channel openers are a group of novel drugs that target KATP channels in the cardiovascular system. This type of K+ channel opens during myocardial ischaemia and plays a part in important endogenous protective mechanisms such as hypoxic/ischaemic coronary vasodilatation and ischaemic preconditioning. By exploiting these natural protective mechanisms of the heart these drugs inhibit myocardial stunning, limit myocardial infarct size, and sensitise the myocardium to ischaemic preconditioning in animal experiments. The cardioprotective effects of the drugs are produced at low concentrations which have no effects in the non-ischaemic myocardium. Most of the drugs are also peripheral vasodilators and some of the first drugs developed are in clinical use as antihypertensive agents. KATP openers which are selective for the ischaemic myocardium have been synthesised and seem to have an interesting therapeutic potential in ischaemic heart disease. Clinical trials have started, but so far there is no clinical experience with pure KATP openers in ischaemic heart disease. Nicorandil, which is a hybrid between a nitrate and a KATP opener, is in clinical use as an effective agent for the treatment of angina pectoris. Pulmonary hypertension and peripheral vascular disease are other potential clinical applications for this novel pharmacological concept of opening cardiovascular K+ channels.
